Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989 Apr;59(4):650–653. doi: 10.1038/bjc.1989.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Coates A., Abraham S., Kaye S. B., Sowerbutts T., Frewin C., Fox R. M., Tattersall M. H. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983 Feb;19(2):203–208. doi: 10.1016/0277-5379(83)90418-2. [DOI] [PubMed] [Google Scholar]
- Gough I. R., Furnival C. M., Burnett W. Patient attitudes to chemotherapy for advanced gastro-intestinal cancer. Clin Oncol. 1981 Mar;7(1):5–11. [PubMed] [Google Scholar]
- Griffiths C. T., Parker L. M., Fuller A. F., Jr Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979 Feb;63(2):235–240. [PubMed] [Google Scholar]
- Hughes J. E. Depressive illness and lung cancer. II. Follow-up of inoperable patients. Eur J Surg Oncol. 1985 Mar;11(1):21–24. [PubMed] [Google Scholar]
- Ozols R. F., Young R. C. Chemotherapy of ovarian cancer. Semin Oncol. 1984 Sep;11(3):251–263. [PubMed] [Google Scholar]
- Weiss G. R. Second-line chemotherapy for ovarian cancer. Clin Obstet Gynecol. 1986 Sep;29(3):665–677. [PubMed] [Google Scholar]
- Young R. C., Chabner B. A., Hubbard S. P., Fisher R. I., Bender R. A., Anderson T., Simon R. M., Canellos G. P., DeVita V. T., Jr Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261–1266. doi: 10.1056/NEJM197812072992301. [DOI] [PubMed] [Google Scholar]